US FDA. Cefepime FDA prescribing information, side effects and uses. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf

Magill SS, O’Leary E, Ray SM, Kainer MA, Evans C, Bamberg WM, Team EIPHPS, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2020;72(10):1784–92. https://doi.org/10.1093/cid/ciaa373.

CAS  Article  Google Scholar 

Okamoto MP, Nakahiro RK, Chin A, Bedikian A. Cefepime clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(2):88–102. https://doi.org/10.2165/00003088-199325020-00002.

CAS  Article  PubMed  Google Scholar 

Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005;43(8):360–9. https://doi.org/10.5414/cpp43360.

CAS  Article  PubMed  Google Scholar 

Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol. 2002;54(12):1693–6. https://doi.org/10.1211/002235702171.

CAS  Article  PubMed  Google Scholar 

Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther. 2000;22(1):66–75. https://doi.org/10.1016/s0149-2918(00)87978-3.

CAS  Article  PubMed  Google Scholar 

Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Ann Pharmacother. 1999;33(12):1258–61. https://doi.org/10.1345/aph.19067.

CAS  Article  PubMed  Google Scholar 

Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Cefepime: a new fourth-generation cephalosporin. Am J Hosp Pharm. 1994;51(4):463–77 (quiz 541–62).

CAS  PubMed  Google Scholar 

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36(3):552–7. https://doi.org/10.1128/aac.36.3.552.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Barbhaiya RH, Knupp CA, Tenney J, Martin RR, Weidler DJ, Pittman KA. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol. 1990;30(10):900–10. https://doi.org/10.1002/j.1552-4604.1990.tb03569.x.

CAS  Article  PubMed  Google Scholar 

Walker P, Neuhauser MN, Tam VH, Willey JS, Palmer JL, Bruera E, et al. Subcutaneous administration of cefepime. J Pain Symptom Manage. 2005;30(2):170–4. https://doi.org/10.1016/j.jpainsymman.2005.03.007.

CAS  Article  PubMed  Google Scholar 

Pilmis B, Mizrahi A, Petitjean G, Le Monnier A, El Helali N. Clinical evaluation of subcutaneous administration of cefepime. Med Mal Infect. 2020;50(3):308–10. https://doi.org/10.1016/j.medmal.2019.12.006.

CAS  Article  PubMed  Google Scholar 

Nye KJ, Shi YG, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother. 1989;24(1):23–8. https://doi.org/10.1093/jac/24.1.23.

CAS  Article  PubMed  Google Scholar 

Kalman D, Barriere SL, Johnson BL Jr. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother. 1992;36(2):453–7. https://doi.org/10.1128/aac.36.2.453.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Okamoto MP, Chin A, Gill MA, Yellin AE, Berne TV, Heseltine PN, et al. Analysis of cefepime tissue penetration into human appendix. Pharmacotherapy. 1991;11(5):353–8.

CAS  PubMed  Google Scholar 

Okamoto MP, Gill MA, Nakahiro RK, Chin A, Yellin AE, Berne TV, et al. Tissue concentrations of cefepime in acute cholecystitis patients. Ther Drug Monit. 1992;14(3):220–5. https://doi.org/10.1097/00007691-199206000-00008.

CAS  Article  PubMed  Google Scholar 

Chadha D, Wise R, Baldwin DR, Andrews JM, Ashby JP, Honeybourne D. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. J Antimicrob Chemother. 1990;25(6):959–63. https://doi.org/10.1093/jac/25.6.959.

CAS  Article  PubMed  Google Scholar 

Arkell D, Ashrap M, Andrews JM, Wise R. An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy. J Antimicrob Chemother. 1992;29(4):473–4. https://doi.org/10.1093/jac/29.4.473.

CAS  Article  PubMed  Google Scholar 

Koufopoulou SA, Pistos C, Giaginis C, Tsantili-Kakoulidou A. Application of the ion pair concept to the n-octanol-water partitioning of cefepime and cefpirome. Int J Pharm. 2006;316(1–2):52–7. https://doi.org/10.1016/j.ijpharm.2006.02.033.

CAS  Article  PubMed  Google Scholar 

Van der Auwera P, Santella PJ. Pharmacokinetics of cefepime: a review. J Antimicrob Chemother. 1993;32(Suppl_B):103–15. https://doi.org/10.1093/jac/32.suppl_B.103.

Article  PubMed  Google Scholar 

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990;48(3):268–76. https://doi.org/10.1038/clpt.1990.149.

CAS  Article  PubMed  Google Scholar 

Cronqvist, J., et al., Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother, 1992;36(12):2676-2680.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Arguedas AG, Stutman HR, Zaleska M, Knupp CA, Marks MI, Nussbaum E. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child. 1992;146(7):797–802. https://doi.org/10.1001/archpedi.1992.02160190029013.

CAS  Article  PubMed  Google Scholar 

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, et al. Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos. 1991;19(1):68–73.

CAS  PubMed  Google Scholar 

Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010;14(2):R51. https://doi.org/10.1186/cc8941.

Article  PubMed  PubMed Central  Google Scholar 

Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53(4):1476–81. https://doi.org/10.1128/aac.01141-08.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother. 1999;43(10):2559–61. https://doi.org/10.1128/aac.43.10.2559.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother. 2006;58(5):987–93. https://doi.org/10.1093/jac/dkl349.

CAS  Article  PubMed  Google Scholar 

Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003;47(6):1853–61. https://doi.org/10.1128/aac.47.6.1853-1861.2003.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg. 2003;97(4):1149–54.

CAS  Article  PubMed  Google Scholar 

Rhodes NJ, Grove ME, Kiel PJ, O’Donnell JN, Whited LK, Rose DT, et al. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. Int J Antimicrob Agents. 2017;50(3):482–6. https://doi.org/10.1016/j.ijantimicag.2017.04.008.

CAS  Article  PubMed  Google Scholar 

Álvarez JC, Cuervo SI, Silva E, Díaz JA, Jiménez LL, Parra DS, et al. Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy. Antibiotics (Basel). 2021;10(5). https://doi.org/10.3390/antibiotics10050504.

Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, et al. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother. 2015;59(9):5463–9. https://doi.org/10.1128/aac.00389-15.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Whited L, Grove M, Rose D, Rhodes NJ, Scheetz MH, O’Donnell JN. Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoeitic cell transplantation. Pharmacotherapy. 2016;36(9):1003–10. https://doi.org/10.1002/phar.1807.

CAS  Article  PubMed  Google Scholar 

Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176–89. https://doi.org/10.1093/jac/dki448.

CAS  Article  PubMed  Google Scholar 

Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23(10):723–9. https://doi.org/10.1016/j.cmi.2017.03.024.

CAS  Article  PubMed  Google Scholar 

Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother. 1993;32 Suppl. B:11